Overcoming barriers to SLT as first line therapy for POAG & OH – Prof. Gus GAZZARD
In this video, Prof. Gus GAZZARD , explains how to overcome barriers to SLT as first line therapy for POAG & OH. This video is from our symposium held at ESCRS 2023.
In this video, Prof. Gus GAZZARD , explains how to overcome barriers to SLT as first line therapy for POAG & OH. This video is from our symposium held at ESCRS 2023.
Glaucoma is a lifelong disease that requires continual monitoring and management. For many patients, glaucoma can be controlled medically—at least for a time—but the treatment is far from perfect. Complications, side effects, and compliance are common issues for those who rely on eye drops to control IOP. Other barriers to medical treatment include nonresponse to a medication, tachyphylaxis, and financial burden.
In this interview, Inder Paul Singh, MD, explains the interest of using SLT as first line therapy for glaucoma instead of medication and the impact on the ocular surface.
«SLT not only takes away the compliance issues that are so difficult for us but it actually addresses the pathology directly.»
Selective laser trabeculoplasty (SLT) has come a long way in the last few years. The practice is gaining adherents as a first-line treatment for open-angle glaucoma for multiple reasons. And to give SLT a boost and provide an uber-coherent overview of the reasons in favor of SLT, Dr. Paul Singh spoke on its behalf at ESCRS 2022 in Milan.
Dr Paul Singh explains what type of patients can benefit from SLT to treat glaucoma.
SLT should be offered to all patients newly diagnosed with primary open-angle glaucoma or ocular hypertension and to those who are not happy on drops. In my practice, I use laser technologies from Lumibird Medical. The Ellex Tango and Quantel Fusion platforms both provide outstanding results for my SLT patient cohorts.
Dr Franck Howes, Eye & Laser Centre Gold Coast (Australia) made a presentation on SLT (Selective Laser Trabeculoplasty) and detailed the process of applying laser energy for the control of glaucoma.
En 2021, el tratamiento láser SLT debería considerarse como el tratamiento de primera línea más indicado para controlar el glaucoma, y debería priorizarse el uso de SubCyclo como opción de tratamiento alternativa a la cirugía.
Cada vez resulta más claro que deberíamos cambiar nuestro modelo de tratamiento para utilizar la SLT como tratamiento primario. Cuanto antes podamos tratar el glaucoma de forma eficaz, mejor podremos reducir la morbilidad de la progresión, además de la necesidad de realizar opciones quirúrgicas más agresivas y la carga que suponen la medicación y los problemas relacionados con el seguimiento de los pacientes.
Como especialista en glaucoma, el producto Fusion de SLT de Quantel Medical me permite estar seguro de estar ofreciendo a mis pacientes la mejor opción como tratamiento de primera línea.
Quantel Medical y Ellex, dos marcas de Lumibird Medical, unidas con un objetivo: desarrollar tecnologías para el diagnóstico y tratamiento del ojo seco y las principales causas de ceguera en el mundo: glaucoma, cataratas, DMAE y retinopatía diabética.
"*" señala los campos obligatorios